CIM
UTHR icon

Calvert Investment Management’s United Therapeutics UTHR Stock Holding History

Calvert Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,717
Closed -$390K – 590
2016
Q4 		$390K Sell
2,717
-78
-3% -$9.96K 0.01% 594
2016
Q3 		$330K Buy
2,795
+76
+3% +$9.13K 0.01% 627
2016
Q2 		$288K Buy
+2,719
New +$303K 0.01% 641
2015
Q2 		– Sell
-2,110
Closed -$364K – 683
2015
Q1 		$364K Buy
2,110
+359
+21% +$54.7K 0.02% 447
2014
Q4 		$227K Buy
1,751
+19
+1% +$2.45K 0.02% 534
2014
Q3 		$223K Buy
+1,732
New +$179K 0.02% 522

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Calvert Investment Management's UTHR Position: Q1 2017 in Review

Calvert Investment Management sold out of United Therapeutics (UTHR) in Q1 2017, closing a stake of 2,717 shares — an estimated $390K sold.

Calvert Investment Management first reported a position in UTHR in Q3 2014 and held it in 6 quarters. The position peaked at $390K in Q4 2016. 411 funds tracked by Wall St. Rank hold UTHR as of Q1 2017.

  • Calvert Investment Management reported no remaining United Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Calvert Investment Management sold 2,717 United Therapeutics shares in Q1 2017, an estimated $390K.
  • Calvert Investment Management first reported a position in United Therapeutics in Q3 2014 and held it in 6 quarters.
  • Calvert Investment Management's United Therapeutics position peaked at $390K in Q4 2016.
  • 411 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.